| 1 |
31087308 | Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs? | 2019 Aug |
1 |
| 2 |
29559479 | Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. | 2018 Jun 14 |
1 |
| 3 |
29690649 | Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. | 2018 Apr 23 |
1 |
| 4 |
27684575 | Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. | 2017 Mar |
3 |
| 5 |
27776353 | Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. | 2017 Jan 24 |
1 |
| 6 |
28178345 | PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors. | 2017 |
1 |
| 7 |
26542378 | A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. | 2016 Jan 28 |
3 |